Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives $34.17 Average Target Price from Brokerages

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) have been given an average recommendation of “Moderate Buy” by the fifteen analysts that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have given a buy rating and two have issued a strong buy rating on the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $34.5833.

DYN has been the subject of a number of recent research reports. Sanford C. Bernstein increased their price objective on Dyne Therapeutics from $23.00 to $24.00 and gave the company a “market perform” rating in a report on Wednesday, May 13th. TD Cowen started coverage on shares of Dyne Therapeutics in a research report on Friday, June 26th. They issued a “buy” rating for the company. Wall Street Zen raised Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Monday, July 6th. Cantor Fitzgerald began coverage on shares of Dyne Therapeutics in a report on Thursday, July 23rd. They issued an “overweight” rating for the company. Finally, Evercore set a $33.00 price target on shares of Dyne Therapeutics in a report on Friday, May 15th.

Insider Activity

In related news, Director Jason P. Rhodes sold 480,240 shares of the stock in a transaction on Monday, July 6th. The shares were sold at an average price of $22.79, for a total transaction of $10,944,669.60. Following the transaction, the director owned 875,912 shares of the company’s stock, valued at approximately $19,962,034.48. This trade represents a 35.41% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders bought 9,000 shares of company stock valued at $156,800 and sold 1,665,542 shares valued at $36,321,576. Insiders own 9.46% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in DYN. Aberdeen Group plc grew its position in Dyne Therapeutics by 99.0% during the 4th quarter. Aberdeen Group plc now owns 1,108,145 shares of the company’s stock valued at $21,675,000 after purchasing an additional 551,412 shares during the last quarter. SG Americas Securities LLC purchased a new position in shares of Dyne Therapeutics in the fourth quarter worth $5,191,000. Fisher Asset Management LLC bought a new position in Dyne Therapeutics during the 4th quarter valued at about $4,891,000. Clearbridge Investments LLC purchased a new stake in shares of Dyne Therapeutics during the 4th quarter valued at about $7,976,000. Finally, Cibc World Market Inc. purchased a new stake in shares of Dyne Therapeutics during the 4th quarter valued at about $1,345,000. 96.68% of the stock is owned by hedge funds and other institutional investors.

Dyne Therapeutics Price Performance

Shares of DYN opened at $25.73 on Tuesday. Dyne Therapeutics has a fifty-two week low of $9.57 and a fifty-two week high of $26.26. The firm has a market capitalization of $4.80 billion, a PE ratio of -7.73 and a beta of 1.06. The company’s 50-day moving average is $21.08 and its 200-day moving average is $18.82. The company has a debt-to-equity ratio of 0.17, a current ratio of 19.92 and a quick ratio of 19.92.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Thursday, July 30th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.34). Equities analysts forecast that Dyne Therapeutics will post -3.01 EPS for the current year.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.